Inventiva：在 Lanifibranor 問世前，MASH 已逐漸轉向聯合療法市場 (NASDAQ:IVA)
· seekingalpha.com
Inventiva 定位為一家高風險的臨床催化劑型公司，憑藉其口服全 PPAR 受體激動劑 lanifibranor 瞄準代謝功能障礙相關脂肪性肝炎 (MASH) 市場。在此閱讀更多關於 IVA 股票的資訊。
My current perspective on Inventiva ( IVA ) comes from a counterintuitive view of the competitive landscape. Although approvals were granted for both Rezdiffra ...